AR012217A1 - A TOPICAL COMPOSITION TO IMPROVE THE PENETRATION OF PHARMACEUTICAL COMPOUNDS - Google Patents

A TOPICAL COMPOSITION TO IMPROVE THE PENETRATION OF PHARMACEUTICAL COMPOUNDS

Info

Publication number
AR012217A1
AR012217A1 ARP980101461A ARP980101461A AR012217A1 AR 012217 A1 AR012217 A1 AR 012217A1 AR P980101461 A ARP980101461 A AR P980101461A AR P980101461 A ARP980101461 A AR P980101461A AR 012217 A1 AR012217 A1 AR 012217A1
Authority
AR
Argentina
Prior art keywords
penetration
topical composition
improve
composition
pharmaceutical compounds
Prior art date
Application number
ARP980101461A
Other languages
Spanish (es)
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of AR012217A1 publication Critical patent/AR012217A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion topica que comprende: a) un compuesto o droga farmacéutica topicamente activa; y b) un sistema solvente buffer que comprende: 1) uncomponente solvente volátil; ii) un componente solvente no volátil; y iii) un componente buffer quefunciona para mantener el pH de la composicion tal queel compuesto farmacéutico permanezca mayormente en su estado ionizado capaz de mejorar la penetracion de dicha droga. El sistema solvente buffer permite a unacantidad reducida del compuesto farmacéutico de la composicion no alterar significativamente la eficacia de dicho compuesto.A topical composition comprising: a) a topically active pharmaceutical compound or drug; and b) a solvent buffer system comprising: 1) a volatile solvent component; ii) a non-volatile solvent component; and iii) a buffer component that works to maintain the pH of the composition such that the pharmaceutical compound remains mostly in its ionized state capable of improving the penetration of said drug. The solvent buffer system allows a reduced amount of the pharmaceutical compound in the composition not to significantly alter the efficacy of said compound.

ARP980101461A 1997-03-31 1998-03-31 A TOPICAL COMPOSITION TO IMPROVE THE PENETRATION OF PHARMACEUTICAL COMPOUNDS AR012217A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82909197A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
AR012217A1 true AR012217A1 (en) 2000-09-27

Family

ID=25253504

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101461A AR012217A1 (en) 1997-03-31 1998-03-31 A TOPICAL COMPOSITION TO IMPROVE THE PENETRATION OF PHARMACEUTICAL COMPOUNDS

Country Status (14)

Country Link
EP (1) EP0971746A1 (en)
JP (1) JP2001518879A (en)
KR (1) KR19980081207A (en)
CN (1) CN1252003A (en)
AR (1) AR012217A1 (en)
AU (1) AU6677698A (en)
BR (1) BR9811458A (en)
CA (1) CA2285368A1 (en)
CO (1) CO5050328A1 (en)
HU (1) HUP0001739A3 (en)
IL (1) IL132096A0 (en)
PL (1) PL335934A1 (en)
WO (1) WO1998043673A1 (en)
ZA (1) ZA982662B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
AU5146600A (en) * 1999-05-27 2000-12-18 Procter & Gamble Company, The Topical compositions providing improved treatment of skin or scalp fungal infections
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP5435836B2 (en) * 2003-07-03 2014-03-05 大正製薬株式会社 Antifungal composition for external use
JP4784051B2 (en) * 2003-07-03 2011-09-28 大正製薬株式会社 Antifungal composition for external use that prevents adsorption to the container
DE102005059742A1 (en) 2005-12-13 2007-06-14 Beiersdorf Ag Transparent sunscreen
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
ES2349906T3 (en) * 2007-07-25 2011-01-12 Ixodes Gmbh TOPICAL ANTIBIOTIC COMPOSITION TO PREVENT LYME DISEASE.
CN101820877B (en) * 2007-08-27 2013-09-11 日本农药株式会社 Agent for fungal dermatitis
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9839611B2 (en) * 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
WO2015077729A2 (en) 2013-11-22 2015-05-28 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
CN115745757B (en) * 2022-11-07 2024-04-26 中国人民解放军军事科学院军事医学研究院 Synthesis of liquid-state polyglycol column arene derivative and application of liquid-state polyglycol column arene derivative in transdermal pharmacodynamic molecule slow release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CN1106259A (en) * 1994-02-05 1995-08-09 日东制药株式会社 Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition

Also Published As

Publication number Publication date
HUP0001739A2 (en) 2000-12-28
KR19980081207A (en) 1998-11-25
CN1252003A (en) 2000-05-03
AU6677698A (en) 1998-10-22
EP0971746A1 (en) 2000-01-19
WO1998043673A1 (en) 1998-10-08
PL335934A1 (en) 2000-05-22
BR9811458A (en) 2000-09-19
CO5050328A1 (en) 2001-06-27
CA2285368A1 (en) 1998-10-08
JP2001518879A (en) 2001-10-16
ZA982662B (en) 1999-09-30
HUP0001739A3 (en) 2001-04-28
IL132096A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
AR012217A1 (en) A TOPICAL COMPOSITION TO IMPROVE THE PENETRATION OF PHARMACEUTICAL COMPOUNDS
ES2526912T3 (en) Pharmaceutical composition containing botulinum neurotoxin A2
BR0313343A (en) Use of a mixture of permeation agents, nail and periungual solutions and use of a nail and periungual solution
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
BR0015605A (en) Composition and use
AR002007A1 (en) A THERAPEUTIC COMPOSITION OF TOPICAL APPLICATION CONTAINING AN ANTAGONIST OF SUBSTANCE P AND USE OF SUCH ANTAGONIST FOR THE PREPARATION OF SUCH COMPOSITION TO DECREASE AND / OR ELIMINATE AN IRRITATING SIDE EFFECT OF A PRODUCT CONTAINED IN IT.
TR199800631A2 (en) Pharmaceutical formulation.
DK1187601T3 (en) A novel composition and form of administration comprising an acid-labile proton pump inhibitor
MX9306295A (en) PHARMACEUTICAL COMPOSITIONS TO TREAT SYMPTOMS OF COLD.
AR003176A1 (en) A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER
BR0114813A (en) Modafinil compound pharmaceutical solutions and their use
BR9812148A (en) 6,9-bridged erythromycin derivatives
ATE339224T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING HONEY FOR WOUND TREATMENT
ECSP930933A (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT
AR000357A1 (en) Use of a substance p antagonist for the preparation of a pharmaceutical composition for topical application to treat cutaneous red spots of neurogenic origin and especially rosacea and pudic erythema
AR030957A1 (en) ANALGESIC AND GLUCOSAMINE COMPOSITIONS
MXPA03004209A (en) Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans cell migration.
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA
AR001247A1 (en) Prepared in the form of patches for the treatment of plants and methods for applying agrochemical agents to plants
ES2180751T3 (en) CANCER METASTASIS INHIBITOR.
AR033596A1 (en) PHARMACEUTICAL COMPOSITION FOR INTRAMUSCULAR INJECTION CONTAINING LOXOPROPHENE
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
ATE300940T1 (en) FUNGAL GROWTH MEDIUM FOR TREATING FUNGAL INFECTIONS